Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study - Sorbonne Université
Journal Articles Digestive and Liver Disease Year : 2020

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study

Pierre Michel
  • Function : Author

Domains

Cancer
Fichier principal
Vignette du fichier
S1590865820303200.pdf (167.39 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04548048 , version 1 (29-11-2024)

Licence

Identifiers

Cite

Sylvain Manfredi, Anthony Turpin, David Malka, Emilie Barbier, Pierre Laurent-Puig, et al.. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study. Digestive and Liver Disease, 2020, 52 (10), pp.1143-1147. ⟨10.1016/j.dld.2020.06.034⟩. ⟨hal-04548048⟩
27 View
0 Download

Altmetric

Share

More